Although rituximab does not carry an indication for the treatment of neurological disorders, the drug is widely used off-label as a therapy for B-cell–mediated disorders like multiple sclerosis (MS). Given the fact that rituximab has not been approved in these indications, however, data that reflect its safety and efficacy—particularly in patient populations for whom data are particularly scarce—are crucial.
Although rituximab does not carry an indication for the treatment of neurological disorders, the drug is widely used off-label as a therapy for B-cell—mediated disorders like multiple sclerosis (MS). The approval of the first US-licensed biosimilar rituximab, Truxima, in 2018, has the potential to make this high-cost treatment option available to more patients, both in its approved indications in oncology and in such off-label applications as the treatment of MS.
Given the fact that rituximab has not been approved in these indications, however, data that reflect its safety and efficacy—particularly in patient populations for whom data are particularly scarce—are crucial. During the upcoming Academy of American Neurology meeting, which will be held May 4-10 in Philadelphia, Pennsylvania, multiple researchers will present on the use of rituximab in patients with MS who are pregnant or breastfeeding.
First, Jessica Rice, MD, of the Oregon Health and Science University in Portland, Oregon, will present a case series in which patients with MS had increased disease activity during pregnancy, although the usual rate of MS relapse typically declines during pregnancy, and many pregnant patients stop taking disease-modifying therapy given concerns about safety.1
In these 2 cases, patients experienced disabling symptoms, and there was concern about further relapses during pregnancy, so the patients were treated with rituximab after risk/benefit considerations.
The first patient, who was treated with rituximab during the third trimester, showed improvement over several weeks, and her infant was born at term without complications. The second patient was treated with rituximab in the early second trimester and has also shown improvement. This patient was in the third trimester at the time of the abstract submission, but no complications had been identified up to that date.
Rice concluded that treating aggressive MS with rituximab during pregnancy has risks, but the drug may be safe and effective when used in an appropriate context.
Researchers from the University of California, San Francisco’s Department of Neurology will report on the concentration of rituximab in the breastmilk of breastfeeding patients with MS. Currently, write the researchers, women with MS have a high risk of postpartum relapse, but due to a lack of data, the standard of care is for them to choose between breastfeeding and resuming MS treatment.2
In the single-center study, the researches collected 6 samples of breast milk from 4 lactating patients who were receiving rituximab. The samples were analyzed using an enzyme-linked immunosorbent assay. The researchers detected only minimal concentrations of rituximab in the samples.
Although the sample size was small, this largest-to-date study of rituximab concentration in breast milk establishes the need for a larger longitudinal study that includes infant outcome measures.
References
1. Rice J. Rituximab for treatment of aggressive multiple sclerosis during pregnancy: a case study. Presented at: 2019 Academy of American Neurology Annual Meeting, May 4-10, 2019; Philadelphia, PA. Abstract P4.2-103.
2. LaHue S, Krysko K, Rutatangwa A, et al. Minimal concentrations of rituximab in the breastmilk of women treated for multiple sclerosis. Presented at: 2019 Academy of American Neurology Annual Meeting, May 4-10, 2019; Philadelphia, PA. Abstract P4.2-097.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
September 16th 2024Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of expanding biosimilars into new therapeutic areas and highlights the role of education, competitive pricing, and integrated delivery networks in improving adoption and market growth.
Real-World Study Shows Comparable Outcomes Between CT-P13, Remicade in RA
September 14th 2024A real-world study of the biosimilar infliximab-dyyb (CT-P13; Inflectra) in rheumatoid arthritis (RA) reported the majority of patients who initiated CT-P13 switched from the reference product (Remicade) or another biologic or targeted synthetic disease-modifying antirheumatic drug.